1643957-24-7

Basic information

• Product Name: Tos-PEG2-CH2CO2tBu
• Synonyms: Tos-PEG2-CH2CO2tBu;tert-Butyl 2-[2-(tosyloxy)ethoxy]acetate
• CAS NO: 1643957-24-7
• Molecular Formula: C15H22O6S
• Molecular Weight: 330.4
• Mol File: 1643957-24-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tos-PEG2-CH2CO2tBu(CAS DataBase Reference)
• NIST Chemistry Reference: Tos-PEG2-CH2CO2tBu(1643957-24-7)
• EPA Substance Registry System: Tos-PEG2-CH2CO2tBu(1643957-24-7)

Safety Data

• Hazardous Substances Data: 1643957-24-7(Hazardous Substances Data)

Usage

Description

Tos-PEG2-CH2CO2tBu is a PEG (polyethylene glycol) linker that features a t-butyl ester and a tosyl group. This molecule is designed to enhance solubility in aqueous environments due to the hydrophilic PEG spacer. The t-butyl protected carboxyl group allows for deprotection under acidic conditions, while the tosyl group serves as an excellent leaving group for nucleophilic substitution reactions, making it a versatile component in various applications.

Uses

Used in Pharmaceutical Industry:
Tos-PEG2-CH2CO2tBu is used as a solubility enhancer for improving the aqueous solubility of drugs, which is crucial for their bioavailability and efficacy. The hydrophilic PEG spacer aids in increasing the solubility of hydrophobic drug molecules, allowing for better absorption and distribution within the body.
Used in Chemical Synthesis:
In the field of chemical synthesis, Tos-PEG2-CH2CO2tBu is used as a protecting group for carboxyl groups during the synthesis of complex molecules. The t-butyl ester can be selectively deprotected under acidic conditions, enabling the controlled release of the carboxyl group at the desired stage of the synthesis.
Used in Bioconjugation:
Tos-PEG2-CH2CO2tBu is used as a bioconjugation agent for the attachment of biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The tosyl group facilitates nucleophilic substitution reactions, allowing for the efficient coupling of the biologically active molecule to the desired target.
Used in Drug Delivery Systems:
In the development of drug delivery systems, Tos-PEG2-CH2CO2tBu is used as a component in the design of targeted drug carriers. The PEG linker can be functionalized with targeting ligands, while the t-butyl ester and tosyl group can be utilized for the controlled release of the drug payload in response to specific stimuli, such as pH changes or enzymatic activity.
Used in Material Science:
In material science, Tos-PEG2-CH2CO2tBu is used as a building block for the creation of stimuli-responsive materials. The PEG linker can be incorporated into polymers or hydrogels, where the t-butyl ester and tosyl group can be used to introduce responsiveness to environmental triggers, such as temperature, pH, or light.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 287174-32-7 (2-hydroxyethoxy)acetic acid tert-butyl ester 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1309451-06-6 2-(2-(benzyloxy)ethoxy)acetic acid tert-butyl ester 

Downstream Products

• 1820717-35-8 2-azidoethoxyacetic acid tert-butyl ester 
• 1155811-37-2 tert-butyl 2-(2-aminoethoxy)acetate 

Relevant articles and documents

Protection of all cleavable sites of DNA with the multiple CGCG or continuous CGG sites from the restriction enzyme, indicative of simultaneous binding of small ligands

The anthracenone ligands (1–12) with a keto-phenol and a hydroxamic acid unit were synthesized and evaluated by a restriction enzyme inhibition assay. DNA substrates composed of multiple CGCG or CGG sites are fully hydrolyzed by a restriction enzyme that is selective for each sequence. Under such conditions, the full-length DNA substrate remains only when the ligand binds to all binding sites and protects it from hydrolysis by the restriction enzymes. In the assay using AccII and the 50-mer DNA substrates containing a different number of CGCG sites at different non-binding AT base pair intervals, the more the CGCG sites, the more the full-length DNA increased. Namely, simultaneous binding of the ligand (5) to the CGCG sites increased in the order of (CGCG)5>(CGCG)2>(CGCG)1. Furthermore, the length of the spacer of the hydroxamic acid to the anthracenone skeleton played an important role in the preference for the number of the d(A/T) base pairs between the CGCG sites. The long spacer-ligand (5) showed a preference to the CGCG sites with five AT pairs, and the short spacer-ligand (10) to that with two AT pairs. The ligand (12) with the shortest spacer showed a preference in simultaneous binding to the 54-mer DNA composed of 16 continuous CGG sites in the assay using the restriction enzyme Fnu4HI that hydrolyzes the d(GCGGC)/d(CGCCG) site. Application of these ligands to biological systems including the repeat DNA sequence should be of significant interest.

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

Oseltamivir PROTAC compound as well as preparation method and application thereof in anti-influenza virus medicines

The invention discloses an oseltamivir PROTAC compound as well as a preparation method and application thereof in anti-influenza virus medicines, and belongs to the technical field of medicines. The oseltamivir PROTAC compound is shown as a general formula (I) or (II), and in the general formula, E3 ligase is a VHL or CRBN ligand, and Linker is a linking group. The compound provided by the invention can effectively degrade influenza virus neuraminidase so as to exert the activity of inhibiting influenza virus replication, not only has inhibitory activity on wild influenza viruses, but also hasa very good inhibitory effect on oseltamivir drug-resistant strains, and has low toxicity to cells. The compound or the pharmacologically or physiologically acceptable salt thereof can be used for preparing anti-influenza virus medicines.